$1,264,240,981

Department of Health and Human Services·Office of Assistant Secretary for Preparedness and Response

to BAVARIAN NORDIC A/S

biotechactiveONGOING · MOD OF 2017 CONTRACT

WORK BEGAN2017-09-27·LATEST ACTION2026-05-11·SOURCEUSASPENDING·SOURCE IDCONT_AWD_HHSO100201700019C_7505_-NONE-_-NONE-

Award description

IGF::OT::IGF

Verbatim from USAspending.gov. Capitalization, abbreviations, and codes are unchanged.

The Buildout's read

What the model surfaced from this award

Confidence: high

In plain English

Latest obligation on the 2017 Bavarian Nordic smallpox/mpox vaccine contract, supporting ongoing production and stockpiling for U.S. pandemic preparedness.

Sub-sectors

vaccine-developmentpandemic-preparednessmpox-countermeasures

Why this matters

Ensures sustained domestic vaccine manufacturing capacity for mpox and smallpox threats; part of HHS's strategic medical countermeasures stockpile strategy.

Supply-chain signal

Bavarian Nordic remains the sole U.S.-approved mpox vaccine supplier; this obligation sustains critical single-source production capacity and supply chain resilience.

U.S.–China competition angle

Secures U.S. independence in vaccine manufacturing for emerging infectious disease threats, reducing reliance on foreign suppliers during health emergencies.

Generated by award_classification v2.1.0 via claude-haiku-4-5-20251001 on 2026-05-17. Cost: $0.003038.

Period of performance

Start

2017-09-27

End

2027-09-26

Status

activein 453 days

Recipient

BAVARIAN NORDIC A/S

UEI D2WABKK2LYX4

View full profile →

Sources

USAspending.gov — all awards for this UEI →
SAM.gov entity registration →
Award record ingested from usaspending. Source identifier CONT_AWD_HHSO100201700019C_7505_-NONE-_-NONE-.

The Buildout does not edit federal records. Any inaccuracy reflects the upstream source; it will update here when corrected there.